CD34+CD38-stem cells and CD34+CD38+progenitor cells as markers of chemotherapy response in acute myeloid leukemia patients

被引：0
作者：
Fergany, Aya [1 ]
Hassanein, Khaled M. [2 ,3 ]
Hameed, Muhamad R. Abdel [4 ]
Kamel, Ayat M. [5 ]
Zahran, Asmaa M. [6 ]
机构：
[1] New Valley Univ, Fac Pharm, Dept Microbiol & Immunol, New Valley, Egypt
[2] Assiut Univ, Fac Med, Dept Med Microbiol & Immunol, Assiut, Egypt
[3] Badr Univ, Dept Microbiol & Immunol, Assiut, Egypt
[4] Assiut Univ, Hosp & Bone Marrow Transplantat Unit, South Egypt Canc Inst, Dept Internal Med, Assiut, Egypt
[5] Assiut Univ, Fac Pharm, Dept Microbiol & Immunol, Assiut, Egypt
[6] Assiut Univ, South Egypt Canc Inst, Dept Clin Pathol, Assiut, Egypt
来源：
IMMUNOPATHOLOGIA PERSA | 2025年 / 11卷 / 02期
关键词：
Acute myeloid leukemia; Complete remission; Flow cytometry; CD34; CD38; Induction chemotherapy; Incomplete remission; Leukemic stem cells; REDUCED IMMUNOGENICITY; HIGH-FREQUENCY; STEM-CELLS; EXPRESSION; HIERARCHY; APOPTOSIS; DIAGNOSIS;
D O I：
10.34172/ipp.2025.43799
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Introduction: CD34+CD38-stem cells were identified as the most related markers to acute myeloid leukemia (AML) progression, resistance, and relapse. However, there is still a lack of published data identifying the level of CD34 and CD38 during induction chemotherapy and after complete remission. Objectives: This study aimed to evaluate the levels of CD34+CD38+progenitor cells and CD34+CD38-stem cells in AML patients at diagnosis and after induction chemotherapy. Patients and Methods: This is a prospective cohort study. Both CD34 and CD38 cell markers were identified using flow cytometry in newly diagnosed AML patients and after induction chemotherapy. Results: Forty newly diagnosed AML patients (27 males and 13 females) were followed up after induction chemotherapy. Results revealed a statistically significant decline (P <= 0.05) in CD34+CD38-stem cell levels as well as in CD34+CD38+progenitor cell levels in AML patients who achieved complete or incomplete remission compared to newly diagnosed AML patients. Besides, age and CD34+CD38-stem cells exhibited a statistically significant positive correlation at diagnosis. Conclusion: Our study showed CD34+CD38-stem cells are associated with disease progression and poor survival in AML patients. We concluded that, CD34 and CD38 are promising follow-up markers for AML patients on induction chemotherapy. In order to keep AML patients in full remission and increase their chances of survival, medications that target leukemic stem cells (LSCs) should be used in conjunction with the usual chemotherapy that targets blasts.
引用
收藏
页数：6
相关论文
共 29 条
[1]   Interleukin-37 gene expression is down-regulated in patients with acute myeloid leukemia and shown to be affected by CD14 and HLA-DR immunophenotypes [J].
Bashi, Mustafa A. ;
Ad'hiah, Ali H. .
CYTOKINE, 2023, 171
[2]   Leukemia stem cells in 2010: Current understanding and future directions [J].
Becker, Michael W. ;
Jordan, Craig T. .
BLOOD REVIEWS, 2011, 25 (02) :75-81
[3]   Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J].
Bonnet, D ;
Dick, JE .
NATURE MEDICINE, 1997, 3 (07) :730-737
[4]   Expression of CD90, CD96, CD117, and CD123 on Different Hematopoietic Cell Populations from Pediatric Patients with Acute Myeloid Leukemia [J].
Chavez-Gonzalez, Antonieta ;
Dorantes-Acosta, Elisa ;
Moreno-Lorenzana, Dafne ;
Alvarado-Moreno, Antonio ;
Arriaga-Pizano, Lourdes ;
Mayani, Hector .
ARCHIVES OF MEDICAL RESEARCH, 2014, 45 (04) :343-350
[5]   Flow cytometric demonstration of decrease in bone marrow leukemic blasts after "Day 14' without further therapy in acute myeloid leukemia [J].
Chen, Xueyan ;
Othus, Megan ;
Wood, Brent L. ;
Walter, Roland B. ;
Percival, Mary-Elizabeth M. ;
Becker, Pamela S. ;
Hendrie, Paul C. ;
Appelbaum, Frederick R. ;
Estey, Elihu H. .
LEUKEMIA & LYMPHOMA, 2017, 58 (11) :2717-2719
[6]  
Costello RT, 2000, CANCER RES, V60, P4403
[7]   The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0):: reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors [J].
Costello, RT ;
Mallet, F ;
Chambost, H ;
Sainty, D ;
Arnoulet, C ;
Gastaut, JA ;
Olive, D .
LEUKEMIA, 1999, 13 (10) :1513-1518
[8]   Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet [J].
Doehner, Hartmut ;
Estey, Elihu H. ;
Amadori, Sergio ;
Appelbaum, Frederick R. ;
Buechner, Thomas ;
Burnett, Alan K. ;
Dombret, Herve ;
Fenaux, Pierre ;
Grimwade, David ;
Larson, Richard A. ;
Lo-Coco, Francesco ;
Naoe, Tomoki ;
Niederwieser, Dietger ;
Ossenkoppele, Gert J. ;
Sanz, Miguel A. ;
Sierra, Jorge ;
Tallman, Martin S. ;
Loewenberg, Bob ;
Bloomfield, Clara D. .
BLOOD, 2010, 115 (03) :453-474
[9]   Tigecycline resistance among Klebsiella pneumoniae isolated from febrile neutropenic patients [J].
Elgendy, Sherein G. ;
Hameed, Muhammad R. Abdel ;
El-Mokhtar, Mohamed A. .
JOURNAL OF MEDICAL MICROBIOLOGY, 2018, 67 (07) :972-975
[10]   Stem cell gene expression programs influence clinical outcome in human leukemia [J].
Eppert, Kolja ;
Takenaka, Katsuto ;
Lechman, Eric R. ;
Waldron, Levi ;
Nilsson, Bjoern ;
van Galen, Peter ;
Metzeler, Klaus H. ;
Poeppl, Armando ;
Ling, Vicki ;
Beyene, Joseph ;
Canty, Angelo J. ;
Danska, Jayne S. ;
Bohlander, Stefan K. ;
Buske, Christian ;
Minden, Mark D. ;
Golub, Todd R. ;
Jurisica, Igor ;
Ebert, Benjamin L. ;
Dick, John E. .
NATURE MEDICINE, 2011, 17 (09) :1086-U91
123